HK inno.N Corporation (KOSDAQ:195940)

Market Cap	1.24T +16.1%
Revenue (ttm)	839.63B +12.9%
Net Income	41.49B +58.1%
EPS	1,451.65 +96.5%
Shares Out	28.33M
PE Ratio	30.10
Forward PE	12.67
Dividend	410.00 (0.84%)
Ex-Dividend Date	Mar 30, 2026

Volume	240,903
Average Volume	184,639
Open	46,100
Previous Close	45,650
Day's Range	42,700 - 46,300
52-Week Range	39,750 - 58,600
Beta	n/a
RSI	29.49
Earnings Date	Apr 28, 2026

About HK inno.N

HK inno.N Corporation engages in the pharmaceutical business in South Korea. The company offers prescription drugs for the treatment of gram-positive and gram-negative organisms, enterococcus faecium infections, vancomycin-resistant, acute bacterial sinusitis, bronchitis, neumonia, antibiotics, and infections caused by microorganism; anemia and hemodialysis; diabetes; hypertension, primary hypercholesterinemia, homozygous familial hypercholesterolemia, and hypertension with dyslipidemia; GERD, EE, NERD, GU and H.Pylori; pleural mesothelioma, no...

• Industry: Medical Care Facilities
• Sector: Healthcare
• Founded: 1984
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 195940

Financial Performance

In 2021, HK inno.N's revenue was 769.79 billion, an increase of 28.63% compared to the previous year's 598.45 billion. Earnings were 21.35 billion, a decrease of -23.49%.